The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning
Open accessAbstract
Risks of secondary solid cancers among allogeneic hematopoietic cell transplant (HCT) recipients who receive conditioning without total body irradiation are not well known. We evaluated the incidence and risk factors for solid cancers after HCT using high-dose busulfan-cyclophosphamide conditioning in 4318 recipients of first allogeneic HCT for acute myeloid leukemia in first complete remission (N = 1742) and chronic myeloid leukemia in first chronic phase (N = 2576). Our cohort represented 22 041 person-years at risk. Sixty-six solid cancers were reported at a median of 6 years after HCT. The cumulative-incidence of solid cancers at 5 and 10 years after HCT was 0.6% and 1.2% among acute myeloid leukemia and 0.9% and 2.4% among chronic myeloid leukemia patients. In comparison to general population incidence rates, HCT recipients had 1.4× higher than expected rate of invasive solid cancers (95% confidence interval, 1.08-1.79, P = .01). Significantly elevated risks were observed for tumors of the oral cavity, esophagus, lung, soft tissue, and brain. Chronic graft-versus-host disease was an independent risk factor for all solid cancers, and especially cancers of the oral cavity. Recipients of allogeneic HCT using busulfan-cyclophosphamide conditioning are at risk for developing solid cancers. Their incidence continues to increase with time, and lifelong cancer surveillance is warranted in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Cited by
Majhail, Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., et al. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120032 · Cited by 509
Majhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., et al. (2012) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2011.12.519 · Cited by 363
Self-citationMajhail, N. S., Rizzo, J. D., Lee, S. J., Aljurf, M., Atsuta, Y., Bonfim, C., Burns, L. J., Chaudhri, N., Davies, S., Okamoto, S., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.5 · Cited by 248
Self-citationSecondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Eapen, M., Brazauskas, R., Williams, D. A., Walters, M. C., St Martin, A., Jacobs, B. L., Antin, J. H., Bona, K., Chaudhury, S., Coleman-Cowger, V. H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01203 · Cited by 60
Self-citationChronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations
Baumrin, E., Loren, A. W., Falk, S. J., Mays, J. W., & Cowen, E. W. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.12.024 · Cited by 59
Retracted
Metadata
- Authors
- Majhail, N. S., Brazauskas, R., Rizzo, J. D., Sobecks, R. M., Wang, Z., Horowitz, M. M., Bolwell, B., Wingard, J. R., & Socie, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-01-06
- Volume
- 117
- Issue
- 1
- Pages
- 316-322
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2017398926
- Cited by
- 223
- References
- 1
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. https://app.cochat.ai/papers/10.1182/blood-2010-07-294629
- The paper
- Majhail, N. S., Brazauskas, R., Rizzo, J. D., Sobecks, R. M., Wang, Z., Horowitz, M. M., Bolwell, B., Wingard, J. R., & Socie, G. (2011). Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. https://doi.org/10.1182/blood-2010-07-294629
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.